<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352715</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5273</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <secondary_id>5UM1AI068634</secondary_id>
    <nct_id>NCT01352715</nct_id>
  </id_info>
  <brief_title>Study of Options for Second-Line Effective Combination Therapy (SELECT)</brief_title>
  <acronym>SELECT</acronym>
  <official_title>Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted on people who were taking their first anti-HIV drug regimen
      (including an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), a type of anti-HIV
      drug) but the drugs in this regimen were not doing a good job of fighting their HIV
      infection.

      The main purpose of this study was to compare two other anti-HIV drug regimens to see how
      well they fight HIV. The study also looked at how well participants tolerate the drug
      regimens and how safe they are.

      The study was designed to determine whether taking the combination of lopinavir/ritonavir
      (LPV/r) plus raltegravir (RAL) works as well as what is usually used for second-line therapy:
      LPV/r plus the best-available nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI)
      combination. Testing a regimen that does not include any NRTIs was important because NRTIs
      may no longer work for patients who received them as part of their first treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As more HIV-infected persons start antiretroviral therapy (ART) worldwide, the number needing
      second-line therapy is increasing. In many settings, an NNRTI-based regimen is the preferred
      first-line ART, whereas a protease inhibitor (PI)-based regimen is often reserved for
      second-line ART. Both of these types of regimens usually include two NRTIs.

      As with initial ART, second-line regimens ideally should be composed of three fully active
      drugs that have potent anti-HIV activity to maximize the chances of durable viral
      suppression. However, such a goal may not be achieved with second-line PI-based regimens
      containing NRTIs because of resistance mutations from first-line therapy that reduce the
      activity of the NRTI class. The most significant of these mutations include M184V, thymidine
      analogue mutations (TAMs), Q151M complex, and K65R. The presence of K65R would result in
      resistance to most NRTIs (leaving only zidovudine (ZDV) and possibly abacavir (ABC) as active
      second-line options); the presence of multiple TAMs and/or Q151M alone or in complex with
      other mutations would also result in resistance to most NRTIs.

      Recent data suggest that patients with isolated M184V-related NRTI resistance who
      subsequently switch to a boosted PI plus lamivudine (3TC)- or emtricitabine (FTC)-based
      regimen may achieve HIV-1 RNA suppression without the need to switch to more complex regimens
      [1]. Detection of an isolated M184V NRTI mutation is possible when resources allow for early
      diagnosis of virologic failure. However, in many resource-limited settings (RLS) early
      diagnosis of virologic failure is difficult because of infrequent monitoring of viral load or
      unavailability of viral load testing. This study intended to provide information applicable
      to the vast majority of RLS where resistance testing is not used routinely for selection of
      second-line regimens and PIs not needing refrigeration are preferred.

      This was a phase III, dual-arm, open-label, randomized, non-inferiority study for
      participants who were on a failing NNRTI-containing first-line regimen. The study evaluated
      the difference in virologic failure rate between two treatment arms:

      Arm A: LPV/r plus RAL Arm B: LPV/r plus best available NRTIs

      Best available NRTI combinations were selected by the site investigator prior to
      randomization from a list of combinations approved by the study or in consultation with the
      A5273 Clinical Management Committee (CMC). The NRTIs provided by the study were FTC/TDF,
      ABC/3TC/ZDV, ABC/3TC, 3TC/ZDV, ABC, 3TC, and ZDV.

      Participants took their assigned study therapy until 96 weeks of follow-up or 52 weeks after
      the last participant was enrolled (protocol amendment), whichever was earlier. This study
      originally planned to enroll 600 participants (300 per study arm), but the sample size was
      re-evaluated to 480 participants (240 per study arm), due to emergent data from other
      studies. Participants were assigned with equal probability to one of the two treatment
      regimens using permuted blocks. Randomization was stratified by three factors: screening
      HIV-1 RNA (≥100,000 versus &lt;100,000 copies/mL); screening CD4+ cell count (≥100 versus &lt;100
      cells/mm3), and selection of ZDV in the NRTI regimen (yes/no). Furthermore, randomization was
      balanced by site.

      During the study, participants were asked to return to the clinic at Weeks 4, 12, 24, and
      then every 12 weeks. Visits lasted about 30 minutes. At most visits, participants had a
      physical exam, had their arm, waist and hip circumference measured, and answered questions
      about their medical condition and any medications they were taking. At some visits,
      participants completed questionnaires to see how they were feeling, if they had been
      hospitalized recently, and how well they were taking their anti-HIV drugs, had their blood
      drawn and were asked to give urine samples. If the participant was female and able to become
      pregnant, a pregnancy test was taken at any visit that pregnancy was suspected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Probability of Virologic Failure by Week 48</measure>
    <time_frame>From study entry to week 48</time_frame>
    <description>The primary endpoint was time to virologic failure. Virologic failure was defined as confirmed viral load &gt;400 copies/mL at or after week 24. The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 48 was used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ Cell Count From Baseline to Week 48</measure>
    <time_frame>Study entry and week 48</time_frame>
    <description>Change in CD4+ cell count was calculated as CD4+ cell count at week 48 minus CD4+ cell count at study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Drug Resistance Mutations in Protease, Reverse Transcriptase, and Integrase in Participants With Virologic Failure at Baseline and at Time of Virologic Failure</measure>
    <time_frame>From study entry through to week 96</time_frame>
    <description>Mutations were defined as major IAS mutations in the IAS-USA July 2014 list. New mutations were those detected at virologic failure but not at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Adverse Event (AE) at Least One Grade Higher Than Baseline</measure>
    <time_frame>From start of randomized treatment to off randomized treatment (up to 96 weeks)</time_frame>
    <description>The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Randomized Treatment for Toxicity</measure>
    <time_frame>From Start of Randomized Treatment to Off Randomized Treatment (up to 96 weeks)</time_frame>
    <description>Discontinuation of randomized treatment for toxicity included participant decision to discontinue for low grade toxicity. Within class NRTI changes were not considered discontinuations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a New AIDS-defining Events or Death</measure>
    <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
    <description>AIDS-defining events were those recognized by the Centers for Disease Control (CDC) and World Health Organization (WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Targeted Serious Non-AIDS-defining Event or Death</measure>
    <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
    <description>Serious non-AIDS diagnoses were based on ACTG Appendix 60 Diagnosis Codes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent in Hospital</measure>
    <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
    <description>The percentage of total study time that participants were in hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fasting Total Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, Triglycerides, and Glucose From Baseline</measure>
    <time_frame>Study entry and week 48</time_frame>
    <description>Fasting was for 8 hours and the metabolic panel was drawn locally.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: LPV/r plus RAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-
FTC/TDF orally twice daily
ABC/3TC/ZDV orally twice daily
ABC/3TC orally once daily
3TC/ZDV orally twice daily
ABC 300mg orally twice daily or 600 mg once daily
3TC orally twice daily
ZDV orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm A: LPV/r plus RAL</arm_group_label>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Aluvia</other_name>
    <other_name>LPV/r</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.</description>
    <arm_group_label>Arm A: LPV/r plus RAL</arm_group_label>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm A: LPV/r plus RAL</arm_group_label>
    <other_name>Isentress</other_name>
    <other_name>RAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate</intervention_name>
    <description>Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Truvada</other_name>
    <other_name>FTC/TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir/lamivudine/zidovudine</intervention_name>
    <description>Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Trizivir</other_name>
    <other_name>ABC/3TC/ZDV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir/lamivudine</intervention_name>
    <description>Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Epzicom</other_name>
    <other_name>ABC/3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/zidovudine</intervention_name>
    <description>Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Combivir</other_name>
    <other_name>CBV</other_name>
    <other_name>3TC/ZDV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <description>Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Ziagen</other_name>
    <other_name>ABC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Retrovir</other_name>
    <other_name>ZDV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.</description>
    <arm_group_label>Arm B: LPV/r plus best available NRTIs</arm_group_label>
    <other_name>Epivir</other_name>
    <other_name>3TC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Confirmation of first-line virologic failure

          -  Certain laboratory values obtained within 45 days prior to study entry. More
             information on this criterion can be found in the study protocol.

          -  Negative pregnancy test within 48 hours prior to study entry.

          -  Must refrain from participating in a conception process, and, if participating in
             sexual activity that could lead to pregnancy, must use at least one acceptable type of
             contraceptive. More information on this criterion can be found in the study protocol.

          -  Karnofsky performance score &gt;= 70 within 45 days prior to study entry.

          -  Ability and willingness of participant or legal guardian/representative to provide
             informed consent.

          -  No intention to relocate away from current geographical area of residence for the
             duration of study participation.

        Exclusion Criteria:

          -  Use of any immunomodulator, HIV vaccine, or other investigational therapy within 45
             days prior to study entry, with the exception of a tapering course of corticosteroids
             as acute therapy for pneumocystis jiroveci pneumonia (PCP) or acute asthma/chronic
             obstructive pulmonary disease flare and/or prednisone at a daily dose of &lt;10 mg
             (physiologic replacement dose).

          -  If the potential participant has had resistance testing, evidence of broad NRTI
             cross-resistance that, in the opinion of the investigator, would not allow selection
             of an effective NRTI combination if the participant were randomized to the LPV/r +
             best available NRTIs arm.

          -  Prior exposure to a Protease Inhibitor.

          -  Known history of congenital long QT syndrome, hypokalemia, or planned use of other
             drugs that prolong the QT interval.

          -  Pregnancy or breast-feeding.

          -  Known history of chronic hepatitis B virus (HBV) infection or current HBV infection
             defined by the presence of hepatitis B surface antigen in serum or plasma.

          -  Active tuberculosis (TB) requiring treatment with rifampicin.

          -  Previously diagnosed malignancies other than basal cell carcinoma and cutaneous Kaposi
             sarcoma.

          -  Requirement for taking any medications that are prohibited with the study drugs. More
             information on this criterion can be found in the study protocol, section 5.4.

          -  Known allergy/sensitivity or any hypersensitivity to components of study drugs or
             their formulation.

          -  Active drug or alcohol use or dependence or other condition that, in the opinion of
             the site investigator, would interfere with adherence to study requirements.

          -  Serious illness requiring systemic treatment and/or hospitalization until candidate
             either completes therapy or is clinically stable on therapy, in the opinion of the
             site investigator, for at least 7 days prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto M La Rosa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociacion Civil Impacta Salud y Educacion - Miraflores, CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann C Collier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Univ. of Washington Clinical HIV Research Program (CHIRP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (12101)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21045</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BJ Medical College CRS (31441)</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NARI Pune CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Y.R.G Ctr, for AIDS Research and Education (11701)</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)</name>
      <address>
        <city>Eldoret</city>
        <zip>30100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Med. JHU CRS (30301)</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lilongwe CRS (12001)</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Miguel CRS</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barranco CRS (11301)</name>
      <address>
        <city>Lima</city>
        <zip>18 PE</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits HIV CRS (11101)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban Adult HIV CRS (11201)</name>
      <address>
        <city>Durban</city>
        <zip>4013 SF</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto ACTG CRS (12301)</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Witwatersrand CRS (11101)</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical CRS</name>
      <address>
        <city>Kilimanjaro Region</city>
        <state>Moshi</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University ACTG CRS (11501)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50202</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ-Parirenyatwa CRS (30313)</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Thailand</country>
    <country>Zimbabwe</country>
  </location_countries>
  <reference>
    <citation>[1] Hull M, Moore D, Harris M, et al. A lamivudine (3TC)-based backbone in conjunction with a boosted protease inhibitor (PI) is sufficient to achieve virologic suppression in the presence of M184V mutations. Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, California. Abstract H-916.</citation>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <results_first_submitted>October 29, 2015</results_first_submitted>
  <results_first_submitted_qc>December 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2016</results_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited at international AIDS Clinical Trials Group Units. Recruitment occurred between March 13, 2012 (date first participant was randomized) and October 2, 2013 (date last participant was randomized).</recruitment_details>
      <pre_assignment_details>515 were randomized 1:1 to treatment arms A and B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: LPV/r Plus RAL</title>
          <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: LPV/r Plus Best Available NRTIs</title>
          <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>site closure</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no final visit in closeout period</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>major ineligibility</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat: All 512 participants without a major eligibility violation.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: LPV/r Plus RAL</title>
          <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: LPV/r Plus Best Available NRTIs</title>
          <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="254"/>
            <count group_id="B3" value="512"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="8"/>
                    <measurement group_id="B2" value="38" spread="8"/>
                    <measurement group_id="B3" value="39" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Regardless of Race)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA</title>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="0.8"/>
                    <measurement group_id="B2" value="4.5" spread="0.9"/>
                    <measurement group_id="B3" value="4.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell count</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178" spread="170"/>
                    <measurement group_id="B2" value="182" spread="160"/>
                    <measurement group_id="B3" value="180" spread="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Probability of Virologic Failure by Week 48</title>
        <description>The primary endpoint was time to virologic failure. Virologic failure was defined as confirmed viral load &gt;400 copies/mL at or after week 24. The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 48 was used.</description>
        <time_frame>From study entry to week 48</time_frame>
        <population>Intention to treat: All 512 participants without a major eligibility violation were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Virologic Failure by Week 48</title>
          <description>The primary endpoint was time to virologic failure. Virologic failure was defined as confirmed viral load &gt;400 copies/mL at or after week 24. The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 48 was used.</description>
          <population>Intention to treat: All 512 participants without a major eligibility violation were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>cumulative probability per 100 persons</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="6.5" upper_limit="14.0"/>
                    <measurement group_id="O2" value="12.4" lower_limit="8.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the difference (arm A - arm B) in the stratified Kaplan-Meier estimate for the week 48 cumulative probability of virologic failure with 95% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Confidence interval estimation was stratified by randomization stratification factors using Greenwood's variance with the inverse of this variance used for the stratum weights. The pre-specified upper confidence bound for non-inferiority was 10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative probability difference</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ Cell Count From Baseline to Week 48</title>
        <description>Change in CD4+ cell count was calculated as CD4+ cell count at week 48 minus CD4+ cell count at study entry.</description>
        <time_frame>Study entry and week 48</time_frame>
        <population>Intention to treat: All 488 participants without a major eligibility violation, and with baseline and week 48 data available were used in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ Cell Count From Baseline to Week 48</title>
          <description>Change in CD4+ cell count was calculated as CD4+ cell count at week 48 minus CD4+ cell count at study entry.</description>
          <population>Intention to treat: All 488 participants without a major eligibility violation, and with baseline and week 48 data available were used in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" lower_limit="181" upper_limit="218"/>
                    <measurement group_id="O2" value="190" lower_limit="171" upper_limit="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Drug Resistance Mutations in Protease, Reverse Transcriptase, and Integrase in Participants With Virologic Failure at Baseline and at Time of Virologic Failure</title>
        <description>Mutations were defined as major IAS mutations in the IAS-USA July 2014 list. New mutations were those detected at virologic failure but not at baseline.</description>
        <time_frame>From study entry through to week 96</time_frame>
        <population>Participants with virologic failure, and with a pair of baseline and virologic failure sequences available, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Drug Resistance Mutations in Protease, Reverse Transcriptase, and Integrase in Participants With Virologic Failure at Baseline and at Time of Virologic Failure</title>
          <description>Mutations were defined as major IAS mutations in the IAS-USA July 2014 list. New mutations were those detected at virologic failure but not at baseline.</description>
          <population>Participants with virologic failure, and with a pair of baseline and virologic failure sequences available, were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No new IAS mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2 new IAS mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 new IAS mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Higher Adverse Event (AE) at Least One Grade Higher Than Baseline</title>
        <description>The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs.</description>
        <time_frame>From start of randomized treatment to off randomized treatment (up to 96 weeks)</time_frame>
        <population>As treated: Participants on randomized treatment are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Adverse Event (AE) at Least One Grade Higher Than Baseline</title>
          <description>The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs.</description>
          <population>As treated: Participants on randomized treatment are included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing Randomized Treatment for Toxicity</title>
        <description>Discontinuation of randomized treatment for toxicity included participant decision to discontinue for low grade toxicity. Within class NRTI changes were not considered discontinuations.</description>
        <time_frame>From Start of Randomized Treatment to Off Randomized Treatment (up to 96 weeks)</time_frame>
        <population>Competing risk approach: Time was measured from start of randomized treatment until the date of randomized treatment discontinuation for toxicity. Randomized treatment discontinuation for other reasons was considered as an independent competing risk, and participants discontinuing the study were censored on the date of last participant contact.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Randomized Treatment for Toxicity</title>
          <description>Discontinuation of randomized treatment for toxicity included participant decision to discontinue for low grade toxicity. Within class NRTI changes were not considered discontinuations.</description>
          <population>Competing risk approach: Time was measured from start of randomized treatment until the date of randomized treatment discontinuation for toxicity. Randomized treatment discontinuation for other reasons was considered as an independent competing risk, and participants discontinuing the study were censored on the date of last participant contact.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a New AIDS-defining Events or Death</title>
        <description>AIDS-defining events were those recognized by the Centers for Disease Control (CDC) and World Health Organization (WHO)</description>
        <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
        <population>Intention to treat: All 512 participants without major eligibility violations were in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a New AIDS-defining Events or Death</title>
          <description>AIDS-defining events were those recognized by the Centers for Disease Control (CDC) and World Health Organization (WHO)</description>
          <population>Intention to treat: All 512 participants without major eligibility violations were in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Targeted Serious Non-AIDS-defining Event or Death</title>
        <description>Serious non-AIDS diagnoses were based on ACTG Appendix 60 Diagnosis Codes</description>
        <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
        <population>Intention to treat: All 512 participants without major eligibility violations were in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Targeted Serious Non-AIDS-defining Event or Death</title>
          <description>Serious non-AIDS diagnoses were based on ACTG Appendix 60 Diagnosis Codes</description>
          <population>Intention to treat: All 512 participants without major eligibility violations were in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent in Hospital</title>
        <description>The percentage of total study time that participants were in hospital.</description>
        <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
        <population>Intention to treat: All 512 participants without a major eligibility violation were in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Hospital</title>
          <description>The percentage of total study time that participants were in hospital.</description>
          <population>Intention to treat: All 512 participants without a major eligibility violation were in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>percentage of time spent in hospital</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08"/>
                    <measurement group_id="O2" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fasting Total Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, Triglycerides, and Glucose From Baseline</title>
        <description>Fasting was for 8 hours and the metabolic panel was drawn locally.</description>
        <time_frame>Study entry and week 48</time_frame>
        <population>Intention to treat: All 512 participants without a major eligibility violation with data available at entry and week 48 were included in their assigned randomized treatment arm. total cholesterol (Arm A N=216 B N=220) HDL (Arm A N=219 B N=223) LDL (Arm A N=202 B N=205) triglycerides (Arm A N=219 B N=222), glucose (Arm A N=213 B N=223)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: LPV/r Plus RAL</title>
            <description>Participants were administered LPV/r plus RAL orally twice daily.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: LPV/r Plus Best Available NRTIs</title>
            <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily.
Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily.
Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fasting Total Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, Triglycerides, and Glucose From Baseline</title>
          <description>Fasting was for 8 hours and the metabolic panel was drawn locally.</description>
          <population>Intention to treat: All 512 participants without a major eligibility violation with data available at entry and week 48 were included in their assigned randomized treatment arm. total cholesterol (Arm A N=216 B N=220) HDL (Arm A N=219 B N=223) LDL (Arm A N=202 B N=205) triglycerides (Arm A N=219 B N=222), glucose (Arm A N=213 B N=223)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total cholesterol change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="O2" value="15" lower_limit="9" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high-density lipoprotein (HDL) cholesterol change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low-density lipoprotein (LDL) cholesterol change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O2" value="10" lower_limit="6" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="51" upper_limit="109"/>
                    <measurement group_id="O2" value="31" lower_limit="13" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>glucose change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study entry throughout follow-up (up to 96 weeks)</time_frame>
      <desc>The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs. Expedited adverse event reporting followed &quot;Manual for Expedited Reporting of Adverse Events to DAIDS&quot; (DAIDS EAE Manual), version 2.0 January, 2010.</desc>
      <group_list>
        <group group_id="E1">
          <title>LPV/r + RAL</title>
          <description>Participants were administered LPV/r plus RAL orally twice daily. Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily. Raltegravir: Raltegravir 400 mg tablet orally twice daily.</description>
        </group>
        <group group_id="E2">
          <title>LPV/r + NRTIs</title>
          <description>Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs.
Lopinavir/ritonavir: Lopinavir 400mg/ritonavir 100mg orally twice daily. Emtricitabine/tenofovir disoproxil fumarate: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily.
Abacavir/lamivudine/zidovudine: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir/lamivudine: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily.
Lamivudine/zidovudine: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily.
Abacavir: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily.
Zidovudine: Zidovudine 300 mg tablet orally twice daily. Lamivudine: Lamivudine 150 mg tablet orally twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS dementia complex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hyperlactacidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Oropharyngeal plaque</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

